

RECEIVED  
CENTRAL FAX CENTER

NOV 18 2004



GlaxoSmithKline

**FAX**

**To** 1647  
.....  
**Company** USPTO  
.....  
**Fax** 703-872-9306  
.....  
**From** Julie D. McFalls  
.....  
**Tel** 919-483-1545 **Fax** 919-483-7988  
.....  
**E-mail** Julie.D.McFalls@gsk.com  
.....  
**Date** November 18, 2004 **Pages including cover** 13  
.....  
**Subject** Serial No.: 10/083,768  
.....  
Filing Date: February 27, 2002  
.....

Glaxo Wellcome Inc.  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
Tel: 919 483 2100  
www.gsk.com

**Attached:**

Amendment and Response to Request for Election of Species  
Combined Amendment and Petition for Extension of Time under 37 CFR 1.136(a)  
Certificate of Transmission

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

NOV 18 2004

PTO/SB/97 (08-09)

Approved for use through 07/31/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the  
United States Patent and Trademark Office

on November 18, 2004  
Date

Julie D. McFalls  
Signature

Julie D. McFalls  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-5199 and select option 2

NOV 18 '04 03:01PM GLAXO WELLCOME

NOV 18 2004

P.3/13

<b>COMBINED AMENDMENT &amp; PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) (Large Entity)</b>					Docket No. PK3065US3	
In Re Application Of: <b>Dower et al.</b>						
Application No. 10/083,768	Filing Date February 27, 2002	Examiner Spector, Lorraine	Customer No. 23347	Group Art Unit 1647	Confirmation No.	
Invention: <b>Peptides and Compounds that Bind to a Thrombopoietin Receptor</b>						
<p><b><u>COMMISSIONER FOR PATENTS:</u></b></p> <p>This is a combined amendment and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of <u>September 22, 2004</u> in the above-identified application. <span style="margin-left: 150px;"><i>Date</i></span></p> <p>The requested extension is as follows (check time period desired):</p> <p> <input checked="" type="checkbox"/> One month                 <input type="checkbox"/> Two months                 <input type="checkbox"/> Three months                 <input type="checkbox"/> Four months                 <input type="checkbox"/> Five months         </p> <p>             from: <u>October 22, 2004</u>     until: <u>November 22, 2004</u>  <span style="margin-left: 100px;"><i>Date</i></span>     <span style="margin-left: 100px;"><i>Date</i></span> </p> <p>The fee for the amendment and extension of time has been calculated as shown below:</p>						
<b>CLAIMS AS AMENDED</b>						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	21 -	20 =	1	x \$18.00	\$18.00	
INDEP. CLAIMS	5 -	3 =	2	x \$88.00	\$176.00	
FEE FOR AMENDMENT					\$194.00	
FEE FOR EXTENSION OF TIME					\$110.00	
<b>TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME</b>					<b>\$304.00</b>	


P2&LARGEREV04

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF  
TIME UNDER 37 CFR 1.136(a) (Large Entity)**Docket No.  
PK3065US3

The fee for the amendment and extension of time is to be paid as follows:

- ☐ A check in the amount of \_\_\_\_\_ for the amendment and extension of time is enclosed.
- ☒ Please charge Deposit Account No. 07-1392 in the amount of \$304.00
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

  
Signature

Virginia G. Campen, Reg. No. 37,092  
Attorney for Applicants  
GlaxoSmithKline  
5 Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1012  
Facsimile: (919) 483-7988

Dated: 18 Nov. 04

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

cc:

P28LARG2/RN04

NOV 18 '04 03:02PM GLAXO WELLCOME

NOV 18 2004

P.5/13

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF  
TIME UNDER 37 CFR 1.136(a) (Large Entity)**

Docket No.  
PK3065US3

In Re Application Of: Dower et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/083,768	February 27, 2002	Spector, Lorraine	23347	1647	

Invention: Peptides and Compounds that Bind to a Thrombopoietin Receptor

**COMMISSIONER FOR PATENTS:**

This is a combined amendment and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of September 22, 2004 in the above-identified application.  
*Date*

The requested extension is as follows (check time period desired):

☒ One month    ☐ Two months    ☐ Three months    ☐ Four months    ☐ Five months

from: October 22, 2004 until: November 22, 2004  
*Date* *Date*

The fee for the amendment and extension of time has been calculated as shown below:

**CLAIMS AS AMENDED**

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	21 -	20 =	1	x \$18.00	\$18.00
INDEP. CLAIMS	5 -	3 =	2	x \$88.00	\$176.00
FEE FOR AMENDMENT					\$194.00
FEE FOR EXTENSION OF TIME					\$110.00
<b>TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME</b>					<b>\$304.00</b>


P28LARGE/REV04

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF  
TIME UNDER 37 CFR 1.136(a) (Large Entity)**Docket No.  
PK3065US3

The fee for the amendment and extension of time is to be paid as follows:

- ☐ A check in the amount of \_\_\_\_\_ for the amendment and extension of time is enclosed.
- ☒ Please charge Deposit Account No. 07-1392 in the amount of \$304.00
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

  
Signature

Virginia G. Campen, Reg. No. 37,092  
Attorney for Applicants  
GlaxoSmithKline  
5 Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1012  
Facsimile: (919) 483-7988

Dated: 18 Nov. 04

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on \_\_\_\_\_

(Date)

\_\_\_\_\_  
Signature of Person Mailing Correspondence

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Correspondence

CC:

P28LARGE/REV04